

ACH-3102 is a potent second generation NS5A inhibitor that was discovered by Achillion. The NS5A protein is a clinically validated mechanism of action whereby it serves multiple functions at various stages of the viral life cycle including involvement in virion production, interacting with host proteins and is implicated in interferon-resistance. ACH-3102 demonstrated in non-clinical studies an excellent target profile, as well as good pharmacokinetic and safety profiles. The unique structure of ACH-3102 maintains high potency against all genotypes of HCV, including genotypes 1a and 1b, and is thought to have potential advantages over first generation NS5A inhibitors by its demonstrated preclinical potency against resistant mutations.

Goals for New HCV Therapeutic Development

- Improving efficacy against the genotype 1 virus
- Offering a treatment response in patients who have failed an interferon and ribavirin-based treatment
- Reducing treatment-related adverse effects
- Offering a more convenient, orally available, treatment option

ACH-3102 AT-A-GLANCE


- **Potency.** Has demonstrated excellent potency against HCV RNA replication in all genotypes at pico-molar concentrations including many common genotype 1a resistant mutants.
- **Combinability.** ACH-3102 is believed to be highly effective in combination regimens *in vitro* and demonstrated highly synergistic activity when combined with an NS3 protease inhibitor and ribavirin.
- **Pharmacokinetics.** ACH-3102 is anticipated to be dosed once-daily.
- **Safety.** Has demonstrated a good safety profile at high doses.

HCV Market Opportunity

It is estimated that over 170 million people are infected with HCV worldwide. The American Association of Liver Disease estimates that up to 85% of individuals become chronically infected following exposure to the virus. The current standard of care for patients with chronic HCV infection is treatment with a combination regimen including long-acting, pegylated forms of interferon alpha (IFN-alpha) administered through weekly injections coupled with twice daily, oral doses of ribavirin. The duration of treatment for HCV patients infected with the genotype 1 virus is 6 to 12 months and is successful in only approximately 70% of patients receiving a full course of treatment. Up to 40% of those patients modify or discontinue therapy due to adverse side effects, including flu-like symptoms, anemia, depression, fatigue, suicidal tendencies and abnormal fetal development.

Preclinical Data and Clinical Development

Preclinical Data ACH-3102 has very high potency in the picomolar range, and is highly active across a broad range of HCV genotypes, including genotype 1a and 1b variants. ACH-3102 exhibits a good safety and pharmacokinetic profile that strongly suggests once-daily dosing, and is highly effective in combination with NS3 protease inhibitor and ribavirin. An IND application for ACH-3102 is expected to be filed during the first half of 2012.



ABOUT ACHILLION Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company's highly skilled and experienced discovery and development teams have identified multiple small molecules with novel mechanisms of action, and is currently advancing three compounds for HCV infection through development. Achillion is focused on solutions for the most challenging problems in hepatitis and resistant bacterial infections.

Achillion Pharmaceuticals, Inc.
300 George Street
New Haven, CT 06511
Main phone: 203.624.7000
Email: info@achillion.com
www.achillion.com